Home › Research › Treatments
Biocatalytic Production of Galantamine in Yeast through Cytochrome P450 Optimization
Holtz M, de Haan S, Castellví Domingo C, Madsen NG, Salazar MDF, Hansson FG, van Aalst ACA, Arnesen JA et al.. bioRxiv, 2026-09-11
Topic: Gut, metabolism and diet
Plain-language summary
Galantamine is a pharmaceutically relevant Amaryllidaceae alkaloid used for the treatment of Alzheimer’s disease. Its structural complexity and low abundance in plants motivate the development of alternative manufacturing routes. Here, we established the first engineered yeast platform for the biocatalytic production of galantamine from 4OMe-norbelladine. Heterologous expression of the downstream pathway enzymes NtCYP96T6, NtNMT1, and NtAKR1 from Narcissus cv. Tête-à-Tête in Saccharomyces cerevisiae was complemented by optimization of cultivation temperature, carbon source, and medium pH enabling the first demonstration of galantamine production in yeast. Systematic screening of cytochrome P450 reductase and cytochrome b₅ partners to boost NtCYP96T6 activity led to the identification of a novel reductase mined from the Narcissus pseudonarcissus transcriptome, NpCPR, which supported the highest pathway flux and yielded 7.0 ± 0.6 mg/L galantamine, corresponding to a 7.6 % molar yield from 250 μM 4OMe-norbelladine and an approximately 173-fold improvement over the parental strain. We further exploited this yeast cell factory for the precursor-directed biosynthesis of 7F-galantamine, highlighting the potential of pathway enzyme promiscuity to access new-to-nature GAL analogues that may be challenging to produce through conventional chemical synthesis. Together, this work establishes a foundation for microbial galantamine production and biosynthetic diversification of its pharmaceutically relevant scaffold.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Holtz, M., de Haan, S., Castellví Domingo, C., Madsen, N. G., Salazar, M. D. F., Hansson, F. G., et al. (2026). Biocatalytic Production of Galantamine in Yeast through Cytochrome P450 Optimization. bioRxiv. https://doi.org/10.64898/2026.09.09.750345
Vancouver
Holtz M, de Haan S, Castellví Domingo C, Madsen NG, Salazar MDF, Hansson FG, et al. Biocatalytic Production of Galantamine in Yeast through Cytochrome P450 Optimization. bioRxiv. 2026. doi:10.64898/2026.09.09.750345.
BibTeX
@article{holtz2026-d33b0eda,
author = {Holtz, M. and de Haan, S. and Castellví Domingo, C. and Madsen, N. G. and Salazar, M. D. F. and Hansson, F. G. and van Aalst, A. C. A. and Arnesen, J. A. and others},
title = {{Biocatalytic Production of Galantamine in Yeast through Cytochrome P450 Optimization}},
journal = {bioRxiv},
year = {2026},
doi = {10.64898/2026.09.09.750345},
url = {https://doi.org/10.64898/2026.09.09.750345}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Heterologous expression of the downstream pathway enzymes NtCYP96T6, NtNMT1, and NtAKR1 from Narcissus cv.
- Tête-à-Tête in Saccharomyces cerevisiae was complemented by optimization of cultivation temperature, carbon source, and medium pH enabling the first demonstration of galantamine production in yeast.
- Systematic screening of cytochrome P450 reductase and cytochrome b₅ partners to boost NtCYP96T6 activity led to the identification of a novel reductase mined from the Narcissus pseudonarcissus transcriptome, NpCPR, which supported the highest pathway flux and yielded 7.0 ± 0.6 mg/L galantamine, corresponding to a 7.6 % molar yield from 250 μM 4OMe-norbelladine and an approximately 173-fold improvement over the parental strain.
- We further exploited this yeast cell factory for the precursor-directed biosynthesis of 7F-galantamine, highlighting the potential of pathway enzyme promiscuity to access new-to-nature GAL analogues that may be challenging to produce through conventional chemical synthesis.
- Together, this work establishes a foundation for microbial galantamine production and biosynthetic diversification of its pharmaceutically relevant scaffold.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 21 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 13 of the 62 points we could judge it on, which is 21 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (bioRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “yeast”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 13 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 13 of the 62 points we could judge it on is 21 out of 100. |
| Total | 21 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “repurposing”
234 studies in the library carry the topic tag “repurposing”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 234 tagged studies.